A Phase 3, Randomized, Double-Blind, Placebo-controlled, Event-driven Study to Demonstrate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, After a Recent Acute Coronary Syndrome

Status

Ongoing, recruiting

Phase

Therapeutic confirmatory (Phase III)

Sponsor

Janssen - Cilag International

Enrolment target

8,535

Start

01 Aug 2023

Age 18 Years to any · Sex: All

• —

  Netherlands
• —

  Latvia
• —

  Denmark
• —

  Portugal
• —

  Czechia
• —

  Germany
• —

  Estonia
• —

  Spain
• —

  France
• —

  Hungary
• —

  Lithuania
• —

  Bulgaria

+8 more sites — see the official record for the full list.